Filings

STAA STAAR SURGICAL CO 10-K 2026-03-03

Item 1A. Risk Factors

tariff on product imports from certain countries, including China. In response, China announced that they would impose counter tariffs on select

10 matches in this document

STAA STAAR SURGICAL CO 10-Q 2025-11-05

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

tariffs by the United States on Chinese goods, China announced retaliatory tariffs on U.S.-origin goods. In order to mitigate

3 matches in this document

STAA STAAR SURGICAL CO 10-Q 2025-08-06

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

tariffs by the United States on Chinese goods, China announced retaliatory tariffs on U.S.-origin goods. In order to mitigate

3 matches in this document

STAA STAAR SURGICAL CO 8-K 2025-09-26

tariffs in the short term (through early 2026), medium and long-term global tariff risks still exist. Further, the risk

5 matches in this document

STAA STAAR SURGICAL CO 8-K 2025-06-04

tariffs through at least early 2026 via consignment inventory strategy Management Transition China Inventory Improving Cash Flow Sales Rebound Tariffs

3 matches in this document

STAA STAAR SURGICAL CO 10-Q 2026-11-04

Item 1 · Note 14. Disaggregation of Sales, Geographic Sales and Product Sales

tariffs imposed by China, the Company negotiated and implemented consignment agreements with its two distributors in China and delivered consigned

7 matches in this document

STAA STAAR SURGICAL CO 8-K 2026-11-04

tariffs imposed on the U.S.-origin products entering China going forward. U.S. product in inventory and sold to China will

6 matches in this document

STAA STAAR SURGICAL CO 10-Q 2026-08-12

Item 1 · Note 14. Disaggregation of Sales, Geographic Sales and Product Sales

tariffs imposed by China, the Company negotiated and implemented consignment agreements with its two distributors in China and delivered consigned

4 matches in this document

STAA STAAR SURGICAL CO 8-K 2026-08-12

tariff expense on U.S. manufactured product sold to China. Margins will continue to be impacted by tariffs until 100% of products

2 matches in this document

STAA STAAR SURGICAL CO 10-Q 2026-05-13

Item 1 · Note 14. Disaggregation of Sales, Geographic Sales and Product Sales

tariffs imposed by China, the Company negotiated and implemented consignment agreements with its two distributors in China and delivered consigned

3 matches in this document

STAA STAAR SURGICAL CO 8-K 2026-03-03

tariff volatility. While this transition has carried incremental and duplicative costs, it helps mitigate tariff exposure, and it significantly strengthens

4 matches in this document

STAA STAAR SURGICAL CO 8-K/A 2026-10-05

tariffs) and substantial dependence on demand from Asia; changes in effective tax rate or tax laws; any loss of use of our principal

1 match in this document

STAA STAAR SURGICAL CO 8-K 2026-09-10

tariffs) and substantial dependence on demand from Asia; changes in effective tax rate or tax laws; any loss of use of our principal

1 match in this document

STAA STAAR SURGICAL CO 8-K 2026-08-06

tariffs) and substantial dependence on demand from Asia; changes in effective tax rate or tax laws; any loss of use of our principal

1 match in this document

STAA STAAR SURGICAL CO 8-K 2026-05-13

environment shaped by tariffs, geopolitical uncertainty, and uneven macroeconomic conditions. Operationally, we are making important advancements across several foundational initiatives.

3 matches in this document

STAA STAAR SURGICAL CO 8-K 2026-04-08

tariffs) and substantial dependence on demand from Asia; changes in effective tax rate or tax laws; any loss of use of our principal

1 match in this document

STAA STAAR SURGICAL CO 8-K 2026-03-03

tariff volatility. There is excitement around the launch of EVO+ in China, and we are working closely with our distributor

2 matches in this document

STAA STAAR SURGICAL CO 8-K 2025-11-05

tariffs) and substantial dependence on demand from Asia; changes in effective tax rate or tax laws; any loss of use of our principal

1 match in this document

STAA STAAR SURGICAL CO 8-K 2025-10-14

Item 8.01.

tariff risks, and the potential for price controls in China. The Board then considered whether to solicit indications of interest

1 match in this document

STAA STAAR SURGICAL CO 8-K 2025-09-26

China, increasing competition, a limited product offering, historical inability to penetrate the market beyond high myopia patients, and tariff risk.

1 match in this document